furosemide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   79 Trials   79 Trials   6783 News 


«12...5960616263646566676869...8687»
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Journal:  Sacubitril-Valsartan Improves Blood Pressure and Heart Failure in Left Ventricular Assist Device (LVAD) Patients. (Pubmed Central) -  May 30, 2020   
    ARNI can improve blood pressure, decrease diuretic requirement, and improve functional capacity in LVAD patients. LVAD speed and medication adjustments may be necessary following ARNI initiation, and in some instances, side effects can limit the ability to sustain ARNI therapy in the setting of LVAD.
  • ||||||||||  Jynarque (tolvaptan) / Otsuka, furosemide / Generic mfg., spironolactone / Generic mfg.
    [VIRTUAL] Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1497;    
    In the Cox regression analysis, short-term response to tolvaptan, average dosages of furosemide and spironolactone during tolvaptan, Child-Pugh classification, and presence of hepatocellular carcinoma were independent factors associated with 1-year survival. This study suggests that the short-term response to tolvaptan and low dosages of conventional diuretics during tolvaptan treatment improve the 1-year and long-term survival rates in cirrhotic patients with hepatic edema, irrespective of liver and kidney function and the presence of hepatocellular carcinoma.
  • ||||||||||  spironolactone / Generic mfg.
    Clinical, Journal:  Diuretic and Renal Effects of Spironolactone and Heart Failure Hospitalizations: A TOPCAT Americas Analysis. (Pubmed Central) -  May 30, 2020   
    This study suggests that the short-term response to tolvaptan and low dosages of conventional diuretics during tolvaptan treatment improve the 1-year and long-term survival rates in cirrhotic patients with hepatic edema, irrespective of liver and kidney function and the presence of hepatocellular carcinoma. In TOPCAT Americas, the benefit of spironolactone on outcomes could not be solely attributed to potential diuretic effects, suggesting the presence of non-diuretic mechanisms.
  • ||||||||||  Frumeron (indapamide) / Remedica
    Clinical, Journal:  The Role of Fractional Excretion of Uric Acid in the Differential Diagnosis of Hypotonic Hyponatraemia in Patients with Diuretic Therapy. (Pubmed Central) -  May 27, 2020   
    Our results show that FEUA discriminated better than sUA between SIAD and DIH patients (area under curve 0.96, <0.001 vs. 0.88, <0.001) while it was a poor marker to discriminate between SIAD and TIH (0.65, NS vs. 0.67, NS). In conclusions, FEUA is an excellent marker to discriminate SIAD vs. sodium depleted patients treated with furosemide and/or potassium canrenoate while the diuretic withdrawal, beyond obtaining a serum Na normalization, is still mandatory for differential diagnosis of sodium depleted patients affected by thiazide-induced hyponatraemia.
  • ||||||||||  metformin / Generic mfg., furosemide / Generic mfg., rosuvastatin / Generic mfg.
    Trial completion:  Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach (clinicaltrials.gov) -  May 27, 2020   
    P1,  N=16, Completed, 
    In conclusions, FEUA is an excellent marker to discriminate SIAD vs. sodium depleted patients treated with furosemide and/or potassium canrenoate while the diuretic withdrawal, beyond obtaining a serum Na normalization, is still mandatory for differential diagnosis of sodium depleted patients affected by thiazide-induced hyponatraemia. Recruiting --> Completed
  • ||||||||||  Actimab-A (lintuzumab-Ac225) / Actinium
    Trial primary completion date:  Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (clinicaltrials.gov) -  May 26, 2020   
    P1/2,  N=72, Active, not recruiting, 
    This study will provide a quantitative basis for explaining the natural medicinal use of LS as a diuretic agent for edema and promoting the diuretic process. Trial primary completion date: Nov 2018 --> Jun 2020
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal. (Pubmed Central) -  May 21, 2020   
    Furosemide tablets were the cheapest (NPR 0.6/10 tablets) and streptokinase injections were the most expensive (NPR 2200/vial) drugs...The lower availability of NCD medicines in the public sector limits the effectiveness of the government's policy of providing free health services at public facilities. Although NCD medicines were generally affordable, future health policy should aim to ensure improved equitable access to NCD medicines, particularly in public facilities.
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Hyponatraemia aggravates cardiac susceptibility to ischaemia/reperfusion injury. (Pubmed Central) -  May 19, 2020   
    The hearts subjected to global ischaemia exhibited considerable decrease in left ventricular developed pressure during reperfusion, and the size of infarcts induced by ischaemia/reperfusion significantly increased in the Fur, Lsd and Fur + Lsd compared with that in the Con. Hyponatraemia aggravates cardiac susceptibility to ischaemia/reperfusion injury by Ca overload and increasing in ROS levels.
  • ||||||||||  atorvastatin / Generic mfg., furosemide / Generic mfg.
    [VIRTUAL] Are patients with coronary heart disease at risk of polypharmacy? () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_513;    
    Patients with CAD are at serious risk of polypharmacy, DDI and FDI. Strategies are needed to reduce medication burden in these patients and to improve their quality of life and knowledge the potential risks of (over)treatment.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] Natriuretic response in elderly patients with acute heart failure () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_421;    
    Initial natriuresis is able to predict in hospital diuretic resistance better than other traditional fluid metrics in an elderly cohort admitted with AHF. Patientes with Nau < 50 mEq/L had an increased risk of early resistance to diuretic treatment, with a need of escalating diuretics and more days of hospitalization.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, Rovi Pharmaceuticals Laboratories
    [VIRTUAL] Influence of sacubitril-valsartan on outcomes of patients with chronic heart failure in different populations: Brazil and Portugal experience. () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_178;    
    Considering ESC guideline for HF therapy, 93.6% x 95.7% were using betablockers (p=0.161), 91.5% x 94.2% ACEI/ARB (p=0.571), 81.8% x 58.8% MRA (p=0.013), 90.9% x 73.9% loop diuretics (p=0.016) and 25% x 15.9% ivabradine (p=0.236), 0% x 15.7% CRT (p=0.006) and 4.5% x 20% ICD (p=0.026)...A significant therapeutic finding was a marked reduction in furosemide dose in both countries post SacVal (Brazil=58.5% x 40.4%, Portugal, p=0,101)... Although there were many differences between Brazil and Portugal populations, the efficacy and safety are the same which showed the great importance of using this new drug in all patients with HFrEF with indication to improve survival and outcomes.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] Creation of predictive models for the early detection of heart failure decompensations () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_106;    
    527 decompensation episodes have been recorded in 150 different patients: 347 were treated at home (253 with oral diuretic adjustment, 79 with iv diuretic and 15 with subcutaneous furosemide infusion pumps)...However, the sensitivity drops from 0.76 with the current alarms to 0.47 with the generated model. Conclusions We have created a predictive model using ML techniques that includes "Weight + Ankle swelling + feeling of clinical worsening + yellow alarms of desaturation SBP, DBP and HR" that improves the accuracy of the alarms currently implemented and obtains better results than those published up to date.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] Efficacy and safety of subcutaneous furosemide in patients with end-stage heart failure () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_103;    
    Of the 13 patients, 7 were alive at the end of the study, the main causes of death being sepsis (N=3, 23.08%), progression of the HF (N=2, 28.57%) or sudden death (N=2, 28.57%). 4 of the 7 patients that are alive, continue with the elastomeric pump (mean dose 91.25 ± 19.48 mg/day) CONCLUSIONS Long-term treatment with sc furosemide in patients with end-stage HF is effective and safe, having significantly reduced episodes of decompensation that have required hospital admission or ED visits, without significant worsening of renal function and without major complications in the puncture site.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] Impact of prehospital i.v. furosemide on hospitalisation outcome in broad spectrum of acute heart failure patients () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_87;    
    4 of the 7 patients that are alive, continue with the elastomeric pump (mean dose 91.25 ± 19.48 mg/day) CONCLUSIONS Long-term treatment with sc furosemide in patients with end-stage HF is effective and safe, having significantly reduced episodes of decompensation that have required hospital admission or ED visits, without significant worsening of renal function and without major complications in the puncture site. Prehospital i.v. furosemide administration in unselected AHF patients population did not show beneficial effect in terms of in-hospital mortality or duration of hospitalization.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, Rovi Pharmaceuticals Laboratories
    [VIRTUAL] Safety of Sacubitril/Valsartan in patients with Glomerular Filtration under 40 () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_55;    
    Our real-life registry supports the safety of SV in patients with GFR 15-40 mL/min in a HFrEF population older and with more comorbidities than in the PARDIGM-HF trial. Not only discontinuation rates were low, but SV also offers some grade of renal function protection in a short-term period after reaching the maximum tolerated dose.
  • ||||||||||  furosemide / Generic mfg.
    [VIRTUAL] Cardiac autonomic nerves stimulation improves hemodynamics and clinical status in advanced heart failure patients () -  May 19, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_51;    
    Patients received at least 80 mg/day of furosemide, had minimal change to existing heart failure medical management, received no new IV vasoactive therapies, and a majority of the patients (17/22) received no furosemide dose uptitration during CANS Therapy. Alongside concomitant medical therapy, CANS holds promise as a tool to improve in-hospital hemodynamics and relieve congestion.
  • ||||||||||  vancomycin / Generic mfg.
    Clinical, Journal:  Vancomycin-Associated Nephrotoxicity and Risk Factors in Critically Ill Children Without Preexisting Renal Injury. (Pubmed Central) -  May 17, 2020   
    Furosemide and amphotericin B in addition to the vancomycin treatment are strong predictors of worse pRIFLE scores. The influence of acute kidney injury status at pediatric intensive care unit admission and the method used for renal function assessment might influence the incidence of vancomycin-associated nephrotoxicity and its associated risk factors.
  • ||||||||||  furosemide / Generic mfg.
    Clinical, Journal:  Effect of Furosemide on Urinary Oxygenation in Patients with Septic Shock. (Pubmed Central) -  May 17, 2020   
    PuO2 measurements in patients are reflective of the low values reported in experimental models of sepsis. PuO2 values increased following furosemide administration with a response independently associated with greater diuresis.
  • ||||||||||  furosemide / Generic mfg.
    Journal:  Life-threatening Hypercalcemia as the First Manifestation of Acute Lymphoblastic Leukemia. (Pubmed Central) -  May 17, 2020   
    A 4-year-old boy presented with intermittent episodes of severe hypercalcemia, which improved with intravenous hydration therapy, furosemide and bisphosphonates as the initial manifestation of occult acute lymphoblastic leukemia. Pediatricians should rule out hematological malignancy in patients with severe hypercalcemia.